varespladib has been researched along with Atherosclerosis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrendt, M; Dikkers, A; Gautier, T; Grass, DS; Hurt-Camejo, E; Rader, DJ; Rosengren, B; Tietge, UJ | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Corsini, A; Ferri, N | 1 |
| Fraser, H; Lusis, AJ; Shaposhnik, Z; Trias, J; Wang, X | 1 |
| Chouinard, ML; Christie, RM; Eacho, PI; Fraser, H; Gould, KE; Hislop, C; Reidy, CA; Rick, HL; Trias, J | 1 |
| Fernandez, ML; Fraser, H; Leite, JO; Puglisi, M; Trias, J; Vaishnav, U | 1 |
| Garcia-Garcia, HM; Serruys, PW | 1 |
| Suckling, KE | 1 |
| Suckling, K | 1 |
| Inazu, A | 1 |
4 review(s) available for varespladib and Atherosclerosis
| Article | Year |
|---|---|
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Acute Coronary Syndrome; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Humans; Indoles; Keto Acids; Lipoproteins; Oximes; Phospholipase A2 Inhibitors; Phospholipases A | 2014 |
Phospholipase A2 inhibitors.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Blood Proteins; Humans; Indoles; Inflammation; Keto Acids; Oximes | 2009 |
Phospholipase A2s: developing drug targets for atherosclerosis.
Topics: Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Cytosol; Drug Design; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Lipoproteins; Mice; Oximes; Phospholipase A2 Inhibitors; Phospholipases A2 | 2010 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
1 trial(s) available for varespladib and Atherosclerosis
| Article | Year |
|---|---|
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
5 other study(ies) available for varespladib and Atherosclerosis
| Article | Year |
|---|---|
Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Topics: Acetates; Animals; Aorta; Aortic Diseases; Apolipoprotein E3; Apolipoproteins B; Atherosclerosis; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Group II Phospholipases A2; Humans; Hypercholesterolemia; Indoles; Keto Acids; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Plaque, Atherosclerotic | 2013 |
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
Topics: Acetates; Animals; Apolipoproteins E; Aryldialkylphosphatase; Atherosclerosis; Drug Synergism; Enzyme Inhibitors; Indoles; Keto Acids; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phospholipases A2, Secretory; Pravastatin; Prodrugs | 2009 |
Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
Topics: Acetates; Aneurysm; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Atherosclerosis; Blood Proteins; Cholesterol; Group II Phospholipases A2; Humans; Indoles; Keto Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Phospholipases A2, Secretory | 2009 |
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
Topics: Acetates; Animals; Aorta, Thoracic; Atherosclerosis; Blood Proteins; Cholesterol; Diet, Atherogenic; Granulocyte-Macrophage Colony-Stimulating Factor; Guinea Pigs; Indoles; Interleukin-10; Interleukin-12; Keto Acids; Lipid Metabolism; Magnetic Resonance Imaging; Phospholipase A2 Inhibitors | 2009 |
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Oximes; Phospholipase A2 Inhibitors | 2009 |